Latest News

Bayer Stock Plunges, Bristol Myers Squibb Falls After Negative Drug-Trial Result


The week is off to an ugly start for some pharmaceutical investors.

Bayer said it is halting a trial for asundexian, an experimental cardiovascular drug, due to a lack of efficacy in treating patients with atrial fibrillation, a condition that causes an irregular heartbeat.

The setback for Bayer, the German chemical and drug giant, bodes poorly for a similar experimental drug at Bristol Myers Squibb, known as milvexian.

U.S. Leading Economic Index Drops More Than Expected In October

Previous article

Satya Nadella added $63 billion in market value for Microsoft with a ‘poker move for the ages’

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News